Mental Health Clinics in Black Canyon City, AZ Accepting Medicare
1 Mental Health Clinics found. Showing 1 - 1
 Black Canyon Community Health Center Counselor Medicare: Medicare Enrolled Practice Location: 19251 E Oasis Dr, Black Canyon City, AZ 85324 Phone: 623-374-0200 Fax: 623-374-5576 |
News Archive
APHP selects Bruker´s Biotyper as exclusive MALDI-TOF mass spectrometry for microbial identification
At the 30th Reunion Interdisciplinaire de Chimothérapie Anti-Infectieuse (RICAI), Bruker announces that the Assistance Publique Hôpitaux de Paris (APHP) has selected Bruker´s IVD MALDI Biotyper as their exclusive MALDI-TOF mass spectrometry-based microbial identification tool.
New hope for patients with liver cancer
In patients with unresectable (unable to be removed by surgery) liver cancer, an interventional radiology procedure called triple-drug transcatheter arterial chemoemobolization (TACE) followed by a liver transplant may significantly increase a patient's chance of long-term survival, according to a study published in the December issue of the American Journal of Roentgenology.
Covidien acquires ev3 for $2.6 billion
Covidien, a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of ev3 Inc. for an aggregate consideration of approximately $2.6 billion, net of cash and short-term investments acquired.
Draining blood from the brain of hemorrhagic stroke patients may prevent death
A minimally invasive surgery combining the use of a clot-busting drug and a catheter to drain blood from the brain of hemorrhagic stroke patients reduced swelling and improved patients' prognoses, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.
› Verified 5 days ago